255 results about "Lungs tissues" patented technology

The invention provides a dynamic lung compliance monitoring method based on electrical impedance tomography, and the method comprises the steps: obtaining an electrical impedance signal and pressure-volume curve data, recording a time sequence signal of lung tissue in a dynamic ventilation process through a synchronous collection device, and obtaining an original multi-dimensional data set; aiming at the second feature set, eliminating redundant parameters by applying a feature screening mechanism, and evaluating the importance of each feature in different breathing stages through an information gain algorithm to obtain a third feature set; constructing a dynamic compliance monitoring model through the weighted feature set, and fitting a lung compliance change trend by using a support vector regression algorithm to obtain a real-time prediction result; and according to the updated prediction result, evaluating the improvement degree of the calculation efficiency, and judging whether the real-time performance meets clinical requirements or not by recording the model operation time and the resource occupancy rate so as to obtain final monitoring output.

The invention belongs to the field of pharmacy, and relates to a medicine for treating pulmonary fibrosis, in particular to application of an anti-Gremlin1 antibody to preparation of a medicine for preventing and treating pulmonary fibrosis. The Gremlin1 antibody disclosed by the invention can be applied to prevention and treatment of pulmonary fibrosis, effectively improves bleomycin (BLM)-induced pulmonary fibrosis lesions of mice and improves the survival rate of the mice. Compared with a BLM group, the mouse inspiration capacity (IC) and the lung static compliance (CRS) treated by the Gremlin1 antibody are remarkably improved, the hydroxyproline content in lung tissue is remarkably reduced, and compared with the BLM group, the Ashcroft score, the collagen deposition area in Masson three-color dyeing and the Sirius red dyeing area of an antibody intervention group are remarkably reduced, and the proportion of activated endothelial cells and the proportion of transition-state epithelial cells are remarkably reduced. Therefore, the Gremlin1 antibody can be used for preparing the medicine for preventing and / or treating the pulmonary fibrosis.

The invention belongs to the technical field of medicines, and discloses a common goldenrop decoction active ingredient composition and application thereof in prevention and treatment of human respiratory syncytial virus. The invention relates to application of an active ingredient composition (isoliquiritigenin, baicalein, 6-shogaol, schisandrin B, ferulic acid and methyl salicylate) of Xiaochaihu decoction and / or a derivative of the active ingredient or a pharmaceutically acceptable salt thereof in preparation of medicines for preventing, relieving and / or treating RSV (Respiratory Syndrome Virus) infectious diseases. According to the invention, by establishing a mouse RSV infection model, the effect and the action mechanism of the composition in preventing and treating RSV infection are evaluated. Results show that each dose group can inhibit replication of RSV in mouse lung tissues, relieve pulmonary edema, improve pathological changes of the lung, inhibit expression of inflammatory factors and improve humoral immunity, and the effect is equivalent to that of ribavirin. The radix bupleuri granules have better effects on relieving pulmonary edema and inhibiting virus proliferation compared with small radix bupleuri granules. The composition of the effective components of the common goldenrop can provide a new drug treatment scheme for clinical RSV infectious diseases.

The invention provides a traditional Chinese medicine monomer composition for preventing and / or treating pulmonary fibrosis as well as a preparation and application thereof, and belongs to the technical field of biological medicines. The traditional Chinese medicine monomer composition comprises the following components: schisandrin B and platycodin D. The traditional Chinese medicine monomer composition can obviously reduce fiber cell and collagen deposition, relieve inflammatory cell infiltration, obviously reduce the lung coefficient, alveolar inflammation score and pulmonary fibrosis score, and recover the normal physiological structure of rat lung tissue. The traditional Chinese medicine monomer composition provided by the invention can reduce the expression contents of KL-6, MMP-7, SP-A and SP-D and lung tissue HYP in serum, and has the effects of relieving collagen deposition and alveolar epithelium injury, maintaining alveolar homeostasis and improving pulmonary fibrosis. Therefore, the traditional Chinese medicine composition provided by the invention is definite and reliable in curative effect and can be used for preparing medicines for preventing and / or treating pulmonary fibrosis.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in improving immunity and preparing products for preventing, treating and / or assisting in treating rhinitis. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can reduce the levels of MDA and NO in serum of mice and improve the activity of SOD and CAT and the content of GSH so as to relieve oxidative stress injury; inflammatory cell infiltration of nasal mucosa is reduced, and lung tissue inflammatory mediator level and inflammation-related gene expression are reduced to inhibit inflammation; th1 / Th2 immune balance is regulated, Th2 type cytokines are reduced, Th1 type cytokines are increased, and the high-dosage effect is close to that of loratadine. The strain has a treatment effect on allergic rhinitis through multiple mechanisms, and a new choice is provided for treatment of the strain.

The invention discloses application of swertiflavin in preparation of a medicine for treating infectious pneumonia caused by methicillin-resistant staphylococcus aureus, and relates to the technical field of medicine. It is found for the first time that swertiflavin can significantly reduce the toxicity of staphylococcus aureus by inhibiting the activity of ClpP protein in MRSA. In addition, the swertiflavin shows a remarkable protection effect in the treatment of the MRSA infectious pneumonia. Specifically, the swertiflavin not only can relieve the injury degree of lung tissues, but also can reduce infiltration and aggregation of inflammatory cells in the lung. The discovery shows that the swertiflavin has potential application value in the field of anti-infection treatment. The invention provides a novel treatment strategy, namely, swertiflavin is used as an active ingredient for preparing the medicine for treating the staphylococcus aureus infectious pneumonia.

The present invention belongs to the technical field of antiviral microecological preparations for livestock and poultry, and specifically relates to Bacillus amyloliquefaciens H-6 and its application in the preparation of a medicament for treating or preventing porcine reproductive and respiratory syndrome virus (PRRSV) infection. The preservation number of the said Bacillus amyloliquefaciens is CCTCC NO: M 20242740. This strain can reduce the infection activity of PRRSV cells, inhibit the invasion and infection of PRRSV to cells, and reduce the proliferation of the virus on cells. The anti-infection research at the cell level and the animal body level shows that this strain has a significant anti-PRRSV effect both in vivo and in vitro, can reduce the proliferation of the virus in pigs, reduce the damage of PRRSV infection to lung tissues and organs, effectively control the adverse effects caused by PRRSV infection to the body, and can weaken the clinical symptoms of pigs during PRRSV infection, and can be used for preventing and controlling the occurrence of porcine reproductive and respiratory syndrome.

The invention provides a non-small cell lung cancer biomarker and application thereof, and particularly relates to application of a reagent for detecting snoRNA SNORD78 or a fragment thereof in preparation of a kit, and the kit is used for diagnosing non-small cell lung cancer and / or screening non-small cell lung cancer tissues. Samples obtained from healthy paracancerous lung tissues and non-small cell lung cancer patients in different staging stages are screened, analyzed and verified to find that snoRNA SNORD78 or fragments thereof have significant expression difference in healthy lung tissue samples (paracancerous) and non-small cell lung cancer tissue samples; moreover, obvious expression difference also exists in healthy individual tissues of the non-small cell lung cancer and individual tissues of different stages of the non-small cell lung cancer, a new molecular marker is provided for indicating the non-small cell lung cancer and the disease course development thereof, and a new thought is provided for preventing and / or treating the non-small cell lung cancer.

The invention discloses a formyl peptide receptor 1 polypeptide blocker for resisting acute lung injury and pharmaceutical application thereof. The invention provides a polypeptide with a sequence as shown in Sequence NO.1, and the polypeptide is reported for the first time. Pharmacological activity studies show that the polypeptide shown as Sequence NO.1 can significantly improve lung tissue structure damage of acute lung injury model mice, reduce the level of proinflammatory factors and reduce neutrophil infiltration, and shows an obvious acute lung injury resisting effect. Therefore, the polypeptide as shown in the Sequence NO.1 provided by the invention has a prospect of being developed into the acute lung injury resisting medicine. Specifically, the polypeptide shown as Sequence NO.1 can be used as a unique active ingredient for preparing the medicine for treating and resisting the acute lung injury, and can also be combined with other active ingredients to form a composition for preparing the medicine for treating and resisting the acute lung injury.

Application of a high-purity inonotus obliquus polysaccharide component belongs to the technical field of biological medicine, and the high-purity inonotus obliquus polysaccharide component plays a role in preventing and treating by inhibiting autophagy of lung tissue cells and depending on an lncRNA Rmst pathway, and can reduce the number of autophagosomes in lung tissues and the level of conversion from LC3-I to LC3-II; according to the method, the sugar content of IOP can be remarkably increased compared with crude polysaccharide, the protein content is remarkably reduced, four active components with specific molecular weights are obtained through separation, the molecular weight ranges are definite (IOP-g1gt, IOP-g2gt, IOP-g3gt and IOP-g4), and the requirements of medicine research and development for controllable purity and definite components are met.

The application discloses an application of baicalin in treating coronavirus infectious diseases. The new application of baicalin is verified through in-vitro cell tests and mouse tests infected with human coronavirus HCoV-229E, the technical scheme is novel, and a curative effect test of baicalin in treating pneumonia caused by HCoV-229E virus infection is carried out, and the results show that baicalin has a certain inhibitory effect on HCoV-229E infected cells in vitro; baicalin shows good drug efficacy in lung index and inhibition rate of pneumonia mice infected with HCoV-229E virus, can reduce the virus load of lung tissue of pneumonia mice infected with HCoV-229E virus, increase the proportion of peripheral blood lymphocytes of mice, and reduce the content of IL-2, IL-10, TNF-alpha and IFN-beta in lung tissue of mice.

Methods and systems are described for a high-level approach to organ generation by self-assembly using bioprinting, overcoming longstanding challenges in replicating the intricate architecture and function of complex organs. In some embodiments, these methods are used to produce lung tissues and microtissues, demonstrating how mini-lung constructs can be produced on a small scale through specialized processes and media. In such embodiments, methods and systems for generating bioprinted lung tissues and microtissues are provided, as are tissues made by such methods. The tissues find use in implantation, drug discovery, personalized medicine, and other applications. Methods for the large-scale manufacturing of lung epithelial stem cells are also provided.

The preservation number of the strain is CGMCC (China General Microbiological Culture Collection Center) NO.30979, the preservation date is June 17, 2024, the preservation classification is named as Lactobacillus brevis, and the preservation unit is the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms. The strain is harmless to animals and has the remarkable effects of relieving lung tissue inflammatory infiltration caused by bronchial asthma, reducing release of serum IgE and Th2 type cell factors, inhibiting activation of an NF-kappa B channel and improving allergic airway inflammation. The invention also discloses application of the strain and the thallus component thereof in preparation of drugs for preventing and treating allergic asthma.

The application relates to a fusion protein and application thereof in the field of biotechnology. A polypeptide fragment for specifically recognizing a single-molecule phospholipid membrane and a polypeptide fragment for specifically recognizing a tissue or a cell are connected to form a fusion protein which can be specifically combined to a fat body surface in a non-covalent manner, so that precise targeting of the fat body is realized. The fat body targeting peptide segment can be widely used in the fields of precise drug delivery and vaccine preparation, so as to be used for treating diseases such as cancer, infectious diseases and metabolic diseases. Lung tissues and breast cancer cells are taken as target points, and good targeting of the fat body is realized.

The invention discloses an application of isothunberine or a pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and / or treating asthma diseases. It is found that in an OVA-induced mouse asthma model, the isothunberine significantly reduces airway resistance excited by acetylcholine, improves inflammatory cell infiltration and airway mucus high secretion of asthma model mouse lung tissue, reduces the levels of lgE and OVA-lgE in serum and related inflammatory factors in alveolar lavage fluid, and has the effect of preventing and treating asthma. Therefore, the effect of treating asthma is achieved. Therefore, the isothunberine has the potential of preventing or treating the asthma, provides a new treatment mode for the treatment of the asthma, and has a wide application prospect.

The invention discloses an application of resveratrol in preparation of a medicine for treating pulmonary ischemia reperfusion injury, relates to the technical field of biological medicines, and particularly relates to an application of resveratrol in preparation of a medicine for treating pulmonary ischemia reperfusion injury. The resveratrol is used for preparing the medicine for treating the pulmonary ischemia reperfusion injury, and the resveratrol in the medicine inhibits cell apoptosis by activating an RSPO3 / Wnt / beta-catenin signal channel, so that the pulmonary ischemia reperfusion injury is relieved; the resveratrol in the medicine can relieve the pulmonary ischemia reperfusion injury by inhibiting apoptosis of alveolar macrophages induced by hypoxia / reoxygenation; the conditions for inhibiting apoptosis induced by hypoxia / reoxygenation by adopting resveratrol are as follows: the resveratrol with the concentration of 2.5 mu M is adopted to pretreat macrophages; the resveratrol plays a protection role by activating an RSPO3 / Wnt / beta-catenin signal channel, and a new basis is provided for the medical application; the resveratrol is applied to preparation of the medicine for treating the lung ischemia-reperfusion injury, cell apoptosis is inhibited, and lung tissue injury is relieved.

The present invention discloses the preparation of patchouli flavonoid nanoliposomes and their application in inhalation treatment of acute lung injury, and relates to the field of medical technology. The patchouli flavonoid nanoliposomes provided by the present invention prepare patchouli flavonoids into a liposome dosage form, which has good stability and biocompatibility. The drug is administered to mice with acute lung injury, so that patchouli flavonoids can act on the mouse lungs in a targeted manner, reduce the expression of inflammatory factors such as IL-6, IL-1β and TNF-α in the mouse lungs to relieve inflammation, improve pulmonary edema, and reduce lung tissue damage, while increasing the levels of tight junction factors such as ZO-1, VE-Cadherin, E-Cadherin and Claudin5 to repair lung barrier damage. The present invention is expected to provide an effective strategy for the treatment of acute lung injury.

The invention discloses an application of a compound fresh bamboo juice in a guinea pig asthma model, and relates to the field of medicines, a Hartley albino guinea pig is adopted to construct an OVA induced asthma model, and the model is verified to be successfully constructed through evaluation indexes; evaluating the efficacy of the successfully constructed guinea pig asthma model by using different doses of compound fresh bamboo juice, and evaluating the efficacy of the guinea pig asthma model by scoring guinea pig capsaicin stimulation cough inducing times, alveolar lavage fluid leukocyte number, inflammatory factor content, lung tissue hydroxyproline content and behavioral signs. And evaluating the treatment effect of the compound fresh bamboo juice through Western blot detection, lung histopathology and immunofluorescence staining indexes. In a guinea pig asthma model, high-dose and medium-dose groups of the compound fresh bamboo juice can be used for remarkably reducing the number of cough, reducing the number of white blood cells in alveolar lavage fluid and the level of inflammatory factors and inhibiting pulmonary fibrosis, and a good treatment effect is shown. The results provide powerful support for potential application of the compound fresh bamboo juice in asthma treatment.

The invention discloses a traditional Chinese medicine composition for treating allergic asthma and a preparation method thereof, and the traditional Chinese medicine composition comprises the following components in parts by weight: 2-10 parts of honey-fried ephedra, 3-10 parts of scutellaria baicalensis, 9-15 parts of momordica grosvenori, 9-15 parts of rhizoma dioscoreae nipponicae, 5-10 parts of scalded semen armeniacae amarae, 2-10 parts of liquorice, 3-10 parts of fried fructus perillae, 3-9 parts of fried semen brassicae, 5-10 parts of schizonepeta, 3-10 parts of platycodon grandiflorum and 5-12 parts of fried semen raphani. The pharmaceutical composition disclosed by the invention is a pure traditional Chinese medicine preparation, and can be used for reducing the level of eosinophilic granulocytes, increasing the number of alveolar macrophages and effectively improving abnormal immune response in an asthma process; lesion degrees such as lung tissue inflammatory cell infiltration, alveolar wall edema and goblet cell hyperplasia are relieved; secretion of Th2 type inflammatory cell related factors and IgE is reduced, and finally the effect of treating allergic asthma inflammatory response is achieved.

The invention provides modRNA (Ribonucleic Acid) for treating obliterated bronchitis, and belongs to the technical field of bioengineering. The modRNA for treating obliterated bronchitis provided by the invention is composed of an IL-10 modRNA (Interleukin-10) and an IFN (Interferon)-alpha modRNA (Interferon-alpha) modRNA. The BO treatment effect is achieved by inhibiting bronchial epithelial cell epithelial-mesenchymal transition (EMT), the expression of alpha-SMA and Vimentin in lung tissue can be remarkably reduced, the expression of E-cadherin and Cytokeratin 5 can be up-regulated, microbronchial epithelial injury is repaired, collagen deposition is reduced, and the lung function is improved. The synergistic effect of the two is better than that of single gene therapy, the safety is high, and the controllability is strong.

The invention relates to the technical field of biological medicines, in particular to application of a CD20 inhibitor in treatment of chronic obstructive pulmonary diseases. The CD20 inhibitor can remarkably improve emphysema and small airway collagen deposition in chronic obstructive pulmonary diseases, inhibit expression of inflammatory factors IL-6 and TNF-alpha in lung tissue, reduce the concentration of chemotactic factors CXCL2 in bronchoalveolar lavage fluid and relieve lung inflammation, and the treatment effect is remarkable. Obviously, CD20 can become a potential clinical treatment target of chronic obstructive pulmonary disease.

The invention discloses a preparation method of a pyridopyrimidine compound and application of the pyridopyrimidine compound in preparation of an asthma medicine. The pyridopyrimidine compound provided by the invention is applied to preparation of medicines for preventing / treating asthma, DPPO is applied to prevention and treatment of bronchial asthma, and a new medicine choice is brought to asthma patients. Experimental results show that the DPPO can obviously inhibit attack of asthma and secretion of related inflammatory factors such as IL-1beta, IL-4, IL-5, IL-6, IL-13 and IL-17A, has a relaxation effect on tracheal smooth muscles, has the effects of resisting angiogenesis, airway remodeling and inflammation, and achieves the effect of treating asthma. In addition, current researches show that the asthma pathogenesis is very complex, DPPO can obviously improve pathological changes of mouse lung tissues sensitized by house dust mite extract (HDM) and toluene diisocynate (TDI), and the DPPO has certain universality and can be speculated to have huge application potential in research and development of drugs for treating various asthma.

The invention discloses application of a TGM2 inhibitor in treatment of chronic sinusitis with nasal polyp, asthma and fibrosis complications thereof. Through single cell transcriptome analysis, it is found that the TGM2 is specifically and highly expressed in a macrophage subset (Tgm < 2 + > macrophage) in a CRSwNP sample with asthma, and the TGM2 protein expression level is significantly and positively correlated with the clinical severity of diseases such as CRSwNP and asthma; animal experiments verify that pathological injuries of the nasal cavity and the lung of a Tgm2-knocked-out mouse type 2 inflammation model are relieved, the inflammation of the upper and lower respiratory tracts of the mouse and the fibrosis level of the lung tissue can be remarkably relieved by adopting a small molecule drug ERW1041E for nasal drop administration, and the safety is good; the invention provides a brand-new treatment strategy for patients with diseases related to type 2 inflammation, and has remarkable clinical transformation value and market prospect.

This invention belongs to the field of biomedical technology and discloses the application of KDELR3 inhibitors in the preparation of drugs for the prevention and / or treatment of individual fibrotic diseases. In a wild-type mouse model of pulmonary fibrosis, compared with the control group receiving intratracheal injection of Scr siRNA, intratracheal injection of KDELR3 siRNA significantly reduced the degree of fibrosis in the mouse lung tissue. KDELR3 inhibition significantly reduced collagen deposition and improved lung tissue structural damage. Further mechanistic studies showed that KDELR3 inhibitors can inhibit the differentiation of fibroblasts into myofibroblasts, thereby reducing the production of fibrosis-related extracellular matrix. These results indicate that KDELR3 is a key molecule regulating the occurrence and development of fibrosis, and drugs that can inhibit KDELR3 expression or activity can be used to prevent and treat various fibrotic diseases, including pulmonary fibrosis, laying the foundation for the development of novel drugs that are effective and safe in treating fibrotic diseases.

The present invention provides a molecular marker associated with resistance to Mycoplasma pneumonia lesions in sheep and its application. The molecular marker was screened from the FOXF1 gene in a GWAS of lung tissue pathology scores. DNA was extracted from sheep blood, and the polymorphic sites of 203 Hu sheep were detected using KASPar primers. A least squares model was established, and the genotypes of the polymorphic sites in the 203 Hu sheep were associated with the pneumonia lesion phenotypic data. Ultimately, it was determined that the FOXF1 gene and its related SNPs screened by the present invention can be used as molecular markers associated with resistance to Mycoplasma pneumonia lesions in sheep. The molecular markers associated with resistance to Mycoplasma pneumonia lesions provided by the present invention can be used to screen high-quality meat sheep with high resistance to Mycoplasma pneumonia, providing a genetic engineering method for rapid screening of disease-resistant sheep breeding, and having significant practical application value.

Systems and methods are provided for delivering a therapeutic treatment to a target population of cells (including, but not limited to, tumors, eyeballs, pancreatic tissue, liver tissue, and lung tissue) in a subject. The system includes an injectable aqueous solution in a vial enclosed with a septum. The solution comprises particles containing a therapeutic agent and having a coating surrounding the therapeutic agent, the coating comprising chitosan to provide controlled release of the agent from the particles. The solution also comprises a chitosan polymer in the form of a polymer gel matrix, further providing controlled release of the particles from the aqueous gel environment. There is also provided a method of making a freeze-dried powder placed in a vial containing a chitosan polymer and chitosan-coated particles, the powder when mixed with water forming the above injectable aqueous solution with particles and chitosan gel.

The present invention relates to a treatment of cancer. Here, the inventors discovered that flavin-containing monooxygenase 4 (FM04) expression was increased in lung tumor samples compared with lung healthy tissue. They found that this phenotype was a common feature in lung adenocarcinoma promoted also by translocation of EML4 / ALK as well as by oncogenic KRAS or EGFR using dedicated mouse models. Moreover, FMO4 was strongly increased in human lung tumors compared with healthy lung tissue, and FMO4 expression was inversely correlated with overall survival in patients with lung adenocarcinoma. Importantly, FMO4 protected lung cancer cells against reactive oxidative species-induced apoptosis. Finally, FMO4 loss of function decreased oncogenic KRAS-induced human bronchoalveolar cells transformation in vitro and in vivo. Thus, the present invention relates to an FMO inhibitor for use in the treatment of cancer in a subject in need thereof.

The invention discloses a nucleoside antiviral NHC diester prodrug as shown in a formula I and pharmaceutically acceptable salts thereof, and a preparation method and medical application of the nucleoside antiviral NHC diester prodrug. Pharmacological experiments prove that the compound disclosed by the invention has relatively strong inhibitory activity on replication of multiple RNA viruses. Particularly, the compound has good lung microsome release efficiency, the species difference of the lung release efficiency is small, the consistency of the in-vivo drug effect of the antiviral drug and the in-vivo drug effect of the antiviral drug can be improved, and the risk of species difference of prodrug release antiviral active ingredients is avoided. Therefore, the compound provided by the invention has good broad-spectrum antiviral activity, and can be used as a broad-spectrum antiviral drug for treating various respiratory virus infections.

The application relates to the field of biomedical technology, and discloses an application of a GCA-NAb monoclonal antibody in the preparation of a drug for preventing and / or treating pulmonary fibrosis. The application mainly relates to the application of an amino acid sequence of the GCA-NAb monoclonal antibody as shown in SEQ ID No. 2 in the preparation of the drug for preventing and / or treating pulmonary fibrosis. The GCA-NAb monoclonal antibody can significantly improve pulmonary fibrosis, and can prolong the survival cycle of a mouse model, reduce the proportion of TH17 cells in lung tissues, and slow down the progress of pulmonary fibrosis. In addition, the antibody can directly affect the transformation of fibroblasts, inhibit the transformation of the fibroblasts into myofibroblasts, and thus reduce the fibrosis. The GCA-NAb monoclonal antibody has the characteristics of high efficiency and safety.

The application provides a method for constructing a mouse emphysema model and application, and the method comprises specifically knocking out a PHLDA1 gene in type II alveolar epithelial cells in lung tissue of an animal. Compared with a traditional method for establishing an animal mouse emphysema model by exposing to cigarette smoke, the mouse emphysema model has good stability, can be bred, has a short modeling cycle, and better simulates the lung tissue pathological changes and pathophysiological changes of emphysema patients, and has high consistency with the patients.